Synergistic Anti-Staphylococcal Activity Of Niosomal Recombinant Lysostaphin-LL-37

Somayeh Sadeghi,1,2 Haleh Bakhshandeh,1 Reza Ahangari Cohan,1 Afshin Peirovi,1 Parastoo Ehsani,2 Dariush Norouzian1 1Department of Nano Biotechnology, New Technology Research Group, Pasteur Institute of Iran, Tehran, Iran; 2Department of Molecular Biology, Pasteur Institute of Iran, Tehran, IranCorr...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Sadeghi S, Bakhshandeh H, Ahangari Cohan R, Peirovi A, Ehsani P, Norouzian D
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2019
Materias:	ll-37 lysostaphin sustained release synergy staphylococcus aureus Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/04de4d59654942d8bb8142100916af0c
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:04de4d59654942d8bb8142100916af0c
record_format	dspace
spelling	oai:doaj.org-article:04de4d59654942d8bb8142100916af0c2021-12-02T09:16:28ZSynergistic Anti-Staphylococcal Activity Of Niosomal Recombinant Lysostaphin-LL-371178-2013https://doaj.org/article/04de4d59654942d8bb8142100916af0c2019-12-01T00:00:00Zhttps://www.dovepress.com/synergistic-anti-staphylococcal-activity-of-niosomal-recombinant-lysos-peer-reviewed-article-IJNhttps://doaj.org/toc/1178-2013Somayeh Sadeghi,1,2 Haleh Bakhshandeh,1 Reza Ahangari Cohan,1 Afshin Peirovi,1 Parastoo Ehsani,2 Dariush Norouzian1 1Department of Nano Biotechnology, New Technology Research Group, Pasteur Institute of Iran, Tehran, Iran; 2Department of Molecular Biology, Pasteur Institute of Iran, Tehran, IranCorrespondence: Parastoo EhsaniDepartment of Molecular Biology, Pasteur Institute of Iran, #69 Pasteur Avenue, Tehran 13164, IranTel + 98 21 64112219Fax + 98 21 64112803Email P_ehsani@pasteur.ac.irDariush NorouzianDepartment of Nano Biotechnology, New Technology Research Group, Pasteur Institute of Iran, #69 Pasteur Avenue, Tehran 13164, IranTel + 98 21 64112137Fax + 98 21 66465132Email dnsa@pasteur.ac.irPurpose: Staphylococcus aureus is the most common persistent pathogen in humans, so development of new formulations to combat pathogen invasion is quite necessary.Methods: In the current study, for the first time, the synergistic activity of recombinant lysostaphin and LL-37 peptide was studied against S. aureus. Moreover, different niosomal formulations of the peptide and protein were prepared and analyzed in terms of size, shape, zeta potential, and entrapment efficiency. Also, a long-term antibacterial activity of the best niosomal formulation and free forms was measured against S. aureus in vitro.Results: The optimal niosomal formulation was obtained by mixing the surfactants (span60 and tween60; 2:1 w/w), cholesterol, and dicetylphosphate at a ratio of 47:47:6, respectively. They showed uniform spherical shapes with the size of 565 and 325 nm for lysostaphin and LL-37, respectively. This formulation showed high entrapment efficiency for the peptide, protein, and a slow-release profile over time. Release kinetic was best fitted by Higuchi model indicating a diffusion-based release of the drugs. The lysostaphin/LL-37 niosomal formulation synergistically inhibited growth of S. aureus for up to 72 hours. However, the same amounts of free forms of both anti-microbial agents could not hold the anti-microbial effect and growth was seen in the following 72 hours. Cytotoxicity assay specified that lysostaphin/LL-37 niosomal combination had no deleterious effect on normal fibroblast cells at effective antimicrobial concentrations.Conclusion: This study indicated that the use of lysostaphin in combination with LL-37, either in niosomal or free forms, synergistically inhibited growth of S. aureus in vitro. In addition, niosomal preparation of antimicrobial agents could provide a long-term protection against bacterial infections.Keywords: LL-37, lysostaphin, sustained release, synergy, Staphylococcus aureus  Sadeghi SBakhshandeh HAhangari Cohan RPeirovi AEhsani PNorouzian DDove Medical Pressarticlell-37lysostaphinsustained releasesynergystaphylococcus aureusMedicine (General)R5-920ENInternational Journal of Nanomedicine, Vol Volume 14, Pp 9777-9792 (2019)
institution	DOAJ
collection	DOAJ
language	EN
topic	ll-37 lysostaphin sustained release synergy staphylococcus aureus Medicine (General) R5-920
spellingShingle	ll-37 lysostaphin sustained release synergy staphylococcus aureus Medicine (General) R5-920 Sadeghi S Bakhshandeh H Ahangari Cohan R Peirovi A Ehsani P Norouzian D Synergistic Anti-Staphylococcal Activity Of Niosomal Recombinant Lysostaphin-LL-37
description	Somayeh Sadeghi,1,2 Haleh Bakhshandeh,1 Reza Ahangari Cohan,1 Afshin Peirovi,1 Parastoo Ehsani,2 Dariush Norouzian1 1Department of Nano Biotechnology, New Technology Research Group, Pasteur Institute of Iran, Tehran, Iran; 2Department of Molecular Biology, Pasteur Institute of Iran, Tehran, IranCorrespondence: Parastoo EhsaniDepartment of Molecular Biology, Pasteur Institute of Iran, #69 Pasteur Avenue, Tehran 13164, IranTel + 98 21 64112219Fax + 98 21 64112803Email P_ehsani@pasteur.ac.irDariush NorouzianDepartment of Nano Biotechnology, New Technology Research Group, Pasteur Institute of Iran, #69 Pasteur Avenue, Tehran 13164, IranTel + 98 21 64112137Fax + 98 21 66465132Email dnsa@pasteur.ac.irPurpose: Staphylococcus aureus is the most common persistent pathogen in humans, so development of new formulations to combat pathogen invasion is quite necessary.Methods: In the current study, for the first time, the synergistic activity of recombinant lysostaphin and LL-37 peptide was studied against S. aureus. Moreover, different niosomal formulations of the peptide and protein were prepared and analyzed in terms of size, shape, zeta potential, and entrapment efficiency. Also, a long-term antibacterial activity of the best niosomal formulation and free forms was measured against S. aureus in vitro.Results: The optimal niosomal formulation was obtained by mixing the surfactants (span60 and tween60; 2:1 w/w), cholesterol, and dicetylphosphate at a ratio of 47:47:6, respectively. They showed uniform spherical shapes with the size of 565 and 325 nm for lysostaphin and LL-37, respectively. This formulation showed high entrapment efficiency for the peptide, protein, and a slow-release profile over time. Release kinetic was best fitted by Higuchi model indicating a diffusion-based release of the drugs. The lysostaphin/LL-37 niosomal formulation synergistically inhibited growth of S. aureus for up to 72 hours. However, the same amounts of free forms of both anti-microbial agents could not hold the anti-microbial effect and growth was seen in the following 72 hours. Cytotoxicity assay specified that lysostaphin/LL-37 niosomal combination had no deleterious effect on normal fibroblast cells at effective antimicrobial concentrations.Conclusion: This study indicated that the use of lysostaphin in combination with LL-37, either in niosomal or free forms, synergistically inhibited growth of S. aureus in vitro. In addition, niosomal preparation of antimicrobial agents could provide a long-term protection against bacterial infections.Keywords: LL-37, lysostaphin, sustained release, synergy, Staphylococcus aureus
format	article
author	Sadeghi S Bakhshandeh H Ahangari Cohan R Peirovi A Ehsani P Norouzian D
author_facet	Sadeghi S Bakhshandeh H Ahangari Cohan R Peirovi A Ehsani P Norouzian D
author_sort	Sadeghi S
title	Synergistic Anti-Staphylococcal Activity Of Niosomal Recombinant Lysostaphin-LL-37
title_short	Synergistic Anti-Staphylococcal Activity Of Niosomal Recombinant Lysostaphin-LL-37
title_full	Synergistic Anti-Staphylococcal Activity Of Niosomal Recombinant Lysostaphin-LL-37
title_fullStr	Synergistic Anti-Staphylococcal Activity Of Niosomal Recombinant Lysostaphin-LL-37
title_full_unstemmed	Synergistic Anti-Staphylococcal Activity Of Niosomal Recombinant Lysostaphin-LL-37
title_sort	synergistic anti-staphylococcal activity of niosomal recombinant lysostaphin-ll-37
publisher	Dove Medical Press
publishDate	2019
url	https://doaj.org/article/04de4d59654942d8bb8142100916af0c
work_keys_str_mv	AT sadeghis synergisticantistaphylococcalactivityofniosomalrecombinantlysostaphinll37 AT bakhshandehh synergisticantistaphylococcalactivityofniosomalrecombinantlysostaphinll37 AT ahangaricohanr synergisticantistaphylococcalactivityofniosomalrecombinantlysostaphinll37 AT peirovia synergisticantistaphylococcalactivityofniosomalrecombinantlysostaphinll37 AT ehsanip synergisticantistaphylococcalactivityofniosomalrecombinantlysostaphinll37 AT norouziand synergisticantistaphylococcalactivityofniosomalrecombinantlysostaphinll37
_version_	1718398164190363648

Synergistic Anti-Staphylococcal Activity Of Niosomal Recombinant Lysostaphin-LL-37

Ejemplares similares